| Drug General Information |
| Drug ID |
D0V6DJ
|
| Former ID |
DIB018659
|
| Drug Name |
5-methylurapidil
|
| Synonyms |
5 methylurapidil; 5-methyl-urapidil
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C21H31N5O3
|
| InChI |
InChI=1S/C21H31N5O3/c1-16-19(23(2)21(28)24(3)20(16)27)22-10-7-11-25-12-14-26(15-13-25)17-8-5-6-9-18(17)29-4/h5-6,8-9,22H,7,10-15H2,1-4H3
|
| InChIKey |
HIHZDNKKIUQQSC-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
5416505, 7978603, 8153469, 11111937, 14854814, 17405829, 26753682, 29224677, 46500368, 47440498, 47959989, 48334744, 50064709, 50107230, 50107231, 53778381, 57322879, 78567119, 85208927, 85231281, 90340943, 92098503, 92303222, 103146517, 103299542, 103941453, 104309821, 117588404, 121362076, 124750374, 124800049, 124881772, 124881773, 128064993, 135072905, 135649841, 162841096, 163565229, 178126959, 179150352, 198946634, 232104651
|
| Target and Pathway |
| Target(s) |
Alpha-2C adrenergic receptor |
Target Info |
Antagonist |
[2]
|
|---|
| Alpha-1B adrenergic receptor |
Target Info |
Antagonist |
[3]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretion
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Vitamin D Receptor Pathway
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR downstream signaling
|
|
AMPK Signaling
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 489). |
|---|
| REF 2 | Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists. J Biol Chem. 2001 Jul 6;276(27):25366-71. Epub 2001 Apr 30. |
|---|
| REF 3 | Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol. 2001 Jun;86(2):189-95. |
|---|
